Clinical Trial Update: Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy study of a 10% intravenous immunoglobulin solution in subjects with primary immunodeficiency disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura
• Immunodeficiency Diseases
• Kawasaki Syndrome

Drugs mentioned

• intravenous immunoglobulin 10% solution (intravenous immunoglobulin)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP) | Phase 3 | Status: COMPLETED